Federal Food and Nutrition Grants

The Embassy of the United States of America in Port of Spain seeks to fund creative and sustainable projects which contain a U.S. component and will aid in societal and institutional growth. The Embassy invites organizations meeting the outlined eligibility criteria to submit grant proposals. This is an open competition for non-profit and/or NGOs and social enterprises with offices headquartered in Trinidad and Tobago. Public Affairs Section Port of Spain invites proposals that further contribution to the three pillars of bilateral collaboration between the United States and Trinidad and Tobago (TT): Security, Accountable Governance, and Inclusive Growth. Multiple awards will be granted, with a maximum amount per award of US$50,000. Specifications: The proposal may not exceed 5 double-spaced pages in 12-point, Times New Roman font with 1-inch margins. Proposals must include project summary, duration, objectives, organizational capacity, key personnel, previous grants received and a budget. Please refer to the notice of funding see Link to Additional Information and ensure you follow all the guidelines stipulated there before submitting your application. In order to be eligible to receive an award, all organizations must have an NCAGE (CAGE U.S. organizations), Unique Entity Identifier (UEI) and a valid registration on SAM.gov. All proposals will be subject to the standard Terms and Conditions of Department of State grants. Please see https://www.state.gov/wp-content/uploads/2021/02/U.S.-Department-of-State-Standard-Terms-and-Conditions-10-21-20.pdf for more information. Generally, grants may not be used for salaries, the purchase of equipment over $500 or for refreshment expenses. Applicants must submit applications electronically using [email protected] by July 15, 2024. Disclaimer: Only applicants whose proposals have been selected for award will be contacted. If a proposal is selected for funding, the Department of State has no obligation to provide any additional future funding in connection with the award. Renewal of an award to increase funding or extend the period of performance is at the total discretion of the Department of State.

The "Chronic Pancreatitis Clinical Research Consortium (CPCRC)- Clinical Centers (CPCRC-CCs)" grant aims to fund ongoing studies on chronic pancreatitis and related conditions, with a focus on understanding the risk factors for pancreatic cancer in patients with chronic pancreatitis and newly diagnosed diabetes, by supporting a consortium of clinical centers and a data management center.

This funding opportunity provides financial support to state egg regulatory programs to help them meet national safety standards and improve egg safety oversight.

This funding opportunity provides financial support to Indian Tribes and tribal organizations for engaging AmeriCorps members in community service projects that address various needs, including youth mental health, education, cultural preservation, and health services.

This funding opportunity supports U.S.-based organizations in conducting research to better understand and manage heart-related side effects of cancer treatments, with a focus on improving detection, monitoring, and data sharing.

The purpose of this FOA is to develop and maintain Rapid Response Teams (RRTs) to facilitate long-term improvements and innovation to the national integrated food safety system by unifying and coordinating federal/state/local human and animal food (HAF) emergency response efforts including:1) Strengthening the link among epidemiology, lab and environmental health/regulatory components;2) Improving States' regulatory and surveillance HAF protection programs to include using Incident Command System (ICS)/National Incident Management System (NIMS) principles and a Unified Command structure to conduct integrated responses to all-hazards HAF emergencies, rapidly identifying and removing tainted food from commerce, and conducting root cause investigations to inform future prevention efforts; and3) Addressing supporting components, such as training, data sharing, data analysis, communications, continuous process improvement, and development of best practices and other resources to support national response capacity/capability development.

The purpose of this funding opportunity announcement (FOA) is to support efficient natural history studies alone or in conjunction with the development and validation of clinical outcome assessments (COAs) and/or biomarker studies to address the unmet needs in rare neurodegenerative diseases for children and adults. Through the support of studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare neurodegenerative disease or multiple rare neurodegenerative diseases with similar pathophysiology, and facilitate rare disease product development.

This funding opportunity provides financial support for new and underrepresented researchers in the health sciences to conduct projects aligned with the missions of NIAID or NIDDK.

The U.S. Food and Drug Administration (FDA) seeks applications to develop, implement, and evaluate a human abuse potential (HAP) study of botanical Kratom. FDA has previously warned consumers about the use of Kratom (Mitragyna speciosa), a plant indigenous to Southeast Asia. Kratom alkaloids have demonstrated both affinity and activity at receptor sites known to be associated with abuse, such as mu opioid receptors. Although Kratom use is prevalent, to date, clinical evaluations of its abuse potential have been limited. The proposed HAP study should be performed in accordance with the guidance for industry, "Assessment of Abuse Potential of Drugs," including (but not limited to) the selection of an appropriate comparator(s) and outcome measures, statistical analyses etc. Interested parties, will also complete the submission of an Investigational New Drug (IND) application and obtain Institutional Review Board (IRB) clearance.

This grant provides funding for research aimed at understanding the factors that contribute to health disparities in HIV and aging among racial and ethnic minorities, low-income populations, and other underserved groups, focusing on how multiple health conditions affect their overall well-being and quality of life.

This funding opportunity supports high-risk, multi-center clinical trials aimed at addressing significant health issues related to diabetes, digestive diseases, and kidney disorders, encouraging diverse institutions to apply for impactful research that can transform clinical practices.

The United States Agency for International Development (USAID) Bureau for Humanitarian Assistance (BHA) is seeking applications for funding to support the rapid transportation, delivery, and distribution of shelf-stable, prepackaged commodities to be distributed under the International Food Relief Partnership (IFRP) program. Please refer to the Funding Opportunity Description for a complete description. Private voluntary organizations or cooperatives, including U.S. and non-U.S. nongovernmental organizations (NGOs) may apply. Organizations designated by USAID as public international organizations are also eligible to apply. Issuance of this RFA does not constitute an award commitment on the part of BHA, nor does it commit BHA to pay for costs incurred in the preparation and submission of an application. Applications are submitted at the risk of the applicant. All preparation and submission costs are at the applicants expense. This includes the completion of all required documents for USAID awards. All comments and inquiries regarding the FY 2024 IFRP RFA should be addressed to Benjamin C. Vogler at the following address: [email protected].

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit research designed to capacitate, transform, and scale the delivery of HIV testing, prevention, and care services through pharmacists and pharmacies in US and/or global settings. This includes theadvancement of training curricula to enable pharmacy students, pharmacists, pharmacies, and pharmacy systems to deliver the spectrum of needed HIV services with ease, equity, and effectiveness. This NOFO uses the R21 grant mechanism, while RFA-MH-25-185 uses the R01 mechanism. Projects that lack preliminary data or that propose to pilot a novel intervention may be most appropriate for the R21 mechanism. Applications with preliminary data and those proposing large-scale clinical trials or longitudinal analyses should consider using the R01 mechanism.

This funding opportunity supports small-scale research projects at undergraduate-focused institutions to enhance research capabilities and engage students in biomedical research.

This program provides funding to state, territory, and Tribal governments to purchase local foods from underserved producers and improve food access in communities with limited resources.

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) that were developed for the treatment of type 2 diabetes (T2D) have significant protective effects for cardiac and renal diseases for people with and without diabetes. However, SGLT2i are not currently approved for individuals with type 1 diabetes (T1D) and there is an increased risk of diabetic ketoacidosis (DKA) for this population. Despite this concern, these drugs are increasingly being prescribed off-label for people with T1D. Continuous ketone monitoring (CKM) is a rapidly evolving technology that could be utilized clinically to prevent DKA by an early warning of elevations in ketone levels.The purpose of this NOFO is to solicit applications for studies that will develop and test risk mitigation strategies that involve the clinical integration of CKM for the safe use of SGLT2i for people living with T1D so that they may benefit from the cardiac and renal protection and glucose-lowering effects of this drug class. The NOFO will support short-term, clinical trials to gain and disseminate knowledge on safety and glucose control with CKM and SGLT2i use.Possible topics include testing optimal insulin delivery in open and closed loop systems or multiple daily injections and developing clinical protocols to control or ameliorate elevated ketone levels in individuals with T1D who are receiving adjunct therapy with SGLT2i.

FDA announces the availability of fiscal year (FY) 2024 funds to support one or more projects to 1) collect antimicrobial use data from diverse animal sectors, including domestic livestock, poultry, companion animals (dogs, cats, and horses), and minor species (e.g., fish, sheep, goats, etc.) and 2) contribute to the development of data collection frameworks, including providing data and expertise as resources and a public-private partnership frameworks are established.This grant will support the continued advancement of FDA's initiatives to support antimicrobial stewardship in veterinary settings. It will also support the National Action Plan objectives to engage the animal health community and relevant stakeholders to advance strategies intended to improve understanding of antimicrobial use and foster antimicrobial stewardship in animal agriculture.

This funding supports institutions in developing training programs for predoctoral and postdoctoral researchers in biomedical and clinical fields, with a focus on enhancing diversity and preparing trainees for successful research careers.

This funding opportunity supports interdisciplinary research teams to explore how medical devices can effectively relieve chronic pain while minimizing addiction risks.

This funding opportunity supports promising predoctoral students in health-related fields to receive personalized research training and mentorship, helping them develop into independent research scientists.